Human Cytomegalovirus Infection in Solid-Organ Transplantation

Abstract

Human cytomegalovirus (CMV) continues to be a major threat against solid-organ transplant recipients despite significant advancements in its prophylaxis and therapy. Primary CMV infection or reactivation of latent CMV in the transplant recipients may cause CMV diseases such as flu-like viral syndrome and tissue-invasive CMV disease. In addition, CMV infection in the recipients is associated with graft rejection and higher risk of other opportunistic infections, which are collectively known as the indirect effects of CMV infection. Prevention strategies with antiviral drugs including ganciclovir remarkably decreased CMV disease and the indirect effects. Two commonly employed strategies are universal prophylaxis and preemptive therapy. However, gangciclovir-resistant CMV has emerged due to mutations in CMV UL97 and UL54 genes, now requiring alternative therapeutic options to be developed. This review provides an overview of CMV infection and disease, indirect effects on hosts, prevention strategies, and drug resistance in solid-organ transplant recipients.